Lisata’s Subsidiary Marea Therapeutics Reports Phase 2b TYDAL-TIMI 78 Data Showing Up To 72.2% Triglyceride Reduction With MAR001, Meeting All Part A Objectives

Part A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL

Reductions from baseline of up to 72.2% in participants with triglycerides ≥500 mg/dL strongly support MAR001’s potential in severe hypertriglyceridemia (sHTG); Part B of TYDAL-TIMI 78 trial now enrolling sHTG participants

Favorable and differentiated safety profile, with adverse event rates similar to placebo and no worsening of HbA1c

SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. ("Marea"), a subsidiary of Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata"), today announced that MAR001, its potential first-in-class monoclonal antibody product candidate targeting angiopoietin-like protein 4 (ANGPTL4), met all objectives in Part A of the Phase 2b TYDAL-TIMI 78 trial, reducing triglycerides by up to 72.2% from baseline in participants with triglycerides ≥500 mg/dL, along with a generally favorable and potentially differentiating safety profile including no worsening of HbA1c. The data are being presented today as a late-breaking clinical trial at the American Heart Association (AHA) Scientific Sessions 2026 and were simultaneously published in The New England Journal of Medicine(NEJM).

MAR001 met the primary endpoint at every dose, with statistically significant placebo-adjusted reductions in fasting triglycerides of 39.1% to 45.5% at Week 12 (p<0.001 for all doses), sustained through Week 24. Triglyceride lowering deepened as baseline levels rose: placebo-adjusted reductions reached up to 57.2% in participants with baseline triglycerides ≥300 mg/dL, and reductions from baseline reached up to 72.2% in participants with triglycerides ≥500 mg/dL. At the 900 mg dose, 51.7% of participants reached normal triglyceride levels (<150 mg/dL), versus 3.4% on placebo. MAR001 also significantly reduced remnant cholesterol and was generally well tolerated through 24 weeks, with no cases of pancreatitis and no glycemic signal versus placebo, as measured by HbA1c, a key consideration for the up to 70% of patients with sHTG who also have type 2 diabetes. Marea has initiated enrollment in Part B of TYDAL-TIMI 78 in participants with sHTG.

sHTG substantially increases the risk of acute pancreatitis, a painful, often recurrent and potentially life-threatening condition. Because many people with sHTG also live with type 2 diabetes, obesity or cardiovascular disease, new treatments need to lower triglycerides enough to help prevent pancreatitis without worsening glycemic control or cardiovascular risk.